Tyra Biosciences is advancing a new achondroplasia treatment in its BEACH301 study, testing selective FGFR3 inhibition. The program targets the genetic driver o

Tyra Biosciences is advancing a new achondroplasia treatment in its BEACH301 study, testing selective FGFR3 inhibition. The program targets the genetic driver of the disorder and expands Tyra’s FGFR3 pipeline beyond its recent bladder cancer trial.